Andrew Loblaw - Sunnybrook Research ...

Dr. Andrew Loblaw, MD

Claim this profile

Sunnybrook Health Sciences Centre

Studies Prostate Cancer
Studies Uterine Tumors
8 reported clinical trials
10 drugs studied

Area of expertise

1Prostate Cancer
Andrew Loblaw, MD has run 7 trials for Prostate Cancer. Some of their research focus areas include:
Stage III
Stage I
Stage II
2Uterine Tumors
Andrew Loblaw, MD has run 1 trial for Uterine Tumors.

Affiliated Hospitals

Image of trial facility.
Sunnybrook Health Sciences Centre
Image of trial facility.
Sunnybrook Health Sciences Centre, Odette Cancer Centre

Clinical Trials Andrew Loblaw, MD is currently running

Image of trial facility.

Rectal Hydrogel Spacer

for Prostate Cancer

There are several single institutional series that have reported their experience with salvage radiotherapy options that include EBRT, LDR and HDR brachytherapy. Gastrointestinal (GI) toxicity with salvage radiotherapy range between14-58%, respectively for patients undergoing re-irradiation. There is a concern for an increased risk of fistula development in these patients who receive second course of radiation. Hypofractionation using SABR has been utilized in the re-irradiation setting for prostate cancer with good tumor control and toxicity outcomes. In order to decrease the rectal toxicity, dose to the rectum should be kept as low as possible. Several techniques can be used to achieve this: tighter dosimetric dose painting, better patient or organ immobilization or use of a biodegradable gel. The Investigators ropose a phase I study to assess placement of a hydrogel spacer between the prostate and rectum, in an effort to decrease toxicity and improve patient's bowel quality of life.
Recruiting1 award N/A
Image of trial facility.

Ablative Radiotherapy

for Prostate Cancer

Favorable-risk prostate cancer represent a large proportion of patients diagnosed with prostate cancer and image guided radiation therapy (IGRT) is commonly used to treat these patients using protracted courses of up to 39 treatments over 8 weeks. Stereotactic ablative body radiotherapy (SABR) protocols hold the promise of more convenience, less side effects, less cost and improved system capacity without sacrificing excellent cancer control rates. By the same token, prostate high-dose rate (HDR) brachytherapy boost has been shown to be superior to standard external beam radiation. While two HDR fractions appear to optimize patient convenience and outcomes while minimizing costs, we wanted to determine the tolerability of combining one MR-guided HDR treatment with one SABR treatment to further reduce HDR resource use while maintaining favourable treatment outcomes.
Recruiting1 award Phase 2 & 35 criteria

More about Andrew Loblaw, MD

Clinical Trial Related7 years of experience running clinical trials · Led 8 trials as a Principal Investigator · 2 Active Clinical Trials
Treatments Andrew Loblaw, MD has experience with
  • MRI Assisted Focal Boost With HDR Monotherapy
  • SABR
  • HDR
  • Stereotactic Ablative Body Radiotherapy
  • Focal Salvage HDR Brachytherapy
  • HDR Brachytherapy

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?
What does Andrew Loblaw, MD specialize in?
Is Andrew Loblaw, MD currently recruiting for clinical trials?
Are there any treatments that Andrew Loblaw, MD has studied deeply?
What is the best way to schedule an appointment with Andrew Loblaw, MD?
What is the office address of Andrew Loblaw, MD?
Is there any support for travel costs?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security